WT Wealth Management Has $734,000 Position in Eli Lilly and Company (NYSE:LLY)

WT Wealth Management decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 800 shares of the company’s stock after selling 49 shares during the period. WT Wealth Management’s holdings in Eli Lilly and Company were worth $734,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in LLY. CFM Wealth Partners LLC boosted its stake in Eli Lilly and Company by 72.1% during the 1st quarter. CFM Wealth Partners LLC now owns 7,840 shares of the company’s stock valued at $6,099,000 after purchasing an additional 3,285 shares during the last quarter. Chemistry Wealth Management LLC grew its holdings in Eli Lilly and Company by 4.6% during the first quarter. Chemistry Wealth Management LLC now owns 550 shares of the company’s stock worth $428,000 after buying an additional 24 shares in the last quarter. CIC Wealth LLC grew its holdings in Eli Lilly and Company by 7.8% during the first quarter. CIC Wealth LLC now owns 3,134 shares of the company’s stock worth $2,438,000 after buying an additional 227 shares in the last quarter. Constitution Capital LLC raised its position in Eli Lilly and Company by 653.9% in the 1st quarter. Constitution Capital LLC now owns 3,355 shares of the company’s stock valued at $2,610,000 after buying an additional 2,910 shares during the last quarter. Finally, Davis Investment Partners LLC bought a new position in Eli Lilly and Company during the 1st quarter valued at $636,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Up 0.3 %

NYSE:LLY opened at $909.15 on Wednesday. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53. The stock’s fifty day moving average price is $921.67 and its two-hundred day moving average price is $860.45. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The company has a market cap of $864.06 billion, a P/E ratio of 133.90, a P/E/G ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, analysts expect that Eli Lilly and Company will post 16.49 EPS for the current year.

Wall Street Analysts Forecast Growth

LLY has been the subject of several analyst reports. Citigroup initiated coverage on shares of Eli Lilly and Company in a report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 target price for the company. Bank of America lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Finally, Truist Financial upped their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,002.24.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.